Pin your most used calculators here by clicking the star in the dropdown.
Renal Cell Carcinoma (RCC) Prognosis Panel
Clinical Context & Background
This comprehensive calculator evaluates prognosis for metastatic Renal Cell Carcinoma (mRCC) using both the modern IMDC (Heng) criteria and the historical MSKCC (Motzer) criteria.
Clinical Guideline Note:
The IMDC (Heng) model is the current standard of care for risk stratification in the era of targeted therapy and immunotherapy (e.g., NCCN Guidelines). The MSKCC model is provided for historical context and comparison.
Shared Risk Factors (Both Models)
KPS < 80%: Karnofsky Performance Status less than 80%.
Time to Treatment < 1 year: Less than one year from initial diagnosis to start of systemic therapy.
Anemia: Hemoglobin < Lower Limit of Normal (LLN).
Hypercalcemia: Corrected Calcium > Upper Limit of Normal (ULN).
IMDC (Heng) Specific Factors
Neutrophilia: Neutrophil count > Upper Limit of Normal (ULN).
Thrombocytosis: Platelet count > Upper Limit of Normal (ULN).
MSKCC (Motzer) Specific Factors
High LDH: Lactate Dehydrogenase > 1.5 x Upper Limit of Normal (ULN).
Note: Local laboratory reference ranges for LLN and ULN should always take precedence over typical values.
Formula Logic
IMDC: 0 (Fav), 1-2 (Int), ≥3 (Poor) based on 6 factors.
MSKCC: 0 (Fav), 1-2 (Int), ≥3 (Poor) based on 5 factors.Reference Data
| System | Risk Group | Score | Median OS (Historical) |
|---|---|---|---|
| IMDC (Heng) | Favorable | 0 factors | 43.2 months |
| IMDC (Heng) | Intermediate | 1 - 2 factors | 22.5 months |
| IMDC (Heng) | Poor | ≥ 3 factors | 7.8 months |
| --- | --- | --- | --- |
| MSKCC (Motzer) | Favorable | 0 factors | 30 months |
| MSKCC (Motzer) | Intermediate | 1 - 2 factors | 14 months |
| MSKCC (Motzer) | Poor | ≥ 3 factors | 5 months |
Related Tools
Evidence-based oncology decision support. Verify with clinical guidelines.